Immunotherapy

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

Phoebe Starr

June 2017, Vol 7, No 6 - Immunotherapy

Washington, DC—Adding the investigational drug indoximod, an indole­amine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hema­tology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting. [ Read More ]

New Research Explains Reasons for Latent Metastasis, Charting a Way for Novel Immunotherapies

Jessica Miller

March 2017, Vol 7, No 3 - Immunotherapy

Cancer often returns years after successful treatment, and it often metastasizes to new organs, which is known as latent metastasis. Certain cancer cells, recently labeled as latency competent cancer (LCC) cells, are capable of becoming dormant for extended periods of time, thereby evading the body’s immunity and leading to cancer recurrence in distant organs after the initial remission. [ Read More ]

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

Walter Alexander

March 2017, Vol 7, No 3 - Immunotherapy

Results of a phase 1/2 study that investigated 2 dosing regi­-mens of 2 immunotherapies—the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy)—in patients with previously treated metastatic urothelial carcinoma showed higher response rates and longer median overall survival with the regimen of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg than with the dosing of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg. [ Read More ]